JACKSON LAIZURE: Open Payments
NPI 1437535846 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,825 in 212 payments from 22 companies in 2025. Trend: 2023 $2,131 · 2024 $3,080 · 2025 $3,825
Food & beverage: $3,715Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $668 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $509 |
| Janssen Biotech, Inc. | 27 | $489 |
| Madrigal Pharmaceuticals | 12 | $376 |
| Gilead Sciences, Inc. | 15 | $254 |
| Lilly USA, LLC | 9 | $213 |
| GENZYME CORPORATION | 13 | $202 |
| Ipsen Biopharmaceuticals, Inc | 12 | $167 |
| Aimmune Therapeutics, Inc. | 7 | $155 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $155 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, DUPIXENT, OMVOH, RINVOQ, IQIRVO, CREON.
Industry payments across OK — which companies pay providers there.
